PRISM was founded in 2009 by Dr. Schnitzer, a world-renowned expert in vascular biology with almost four decades of research experience. Upon earning his MD in 1985 from the University of Pittsburgh, he served as a Post-Doctoral Fellow in the Department of Cell Biology, Yale University Medical School, where he began his pioneering work on the caveolae transcytosis transport pathway. He served as Scientific Director for the Sidney Kimmel Cancer Center, San Diego, CA, from 1999-2009 prior to founding PRISM. Dr. Schnitzer has received many awards, including the Established Investigator Award from the American Heart Association, the CaP Cure Award in Cancer, and the Kleinerman Lectureship Award for Pulmonary Pathobiology. Over the last two decades, he has served as Associate Editor of several journals and on the Scientific Advisory Board of several companies. He is the recipient of several multi-million dollar NIH grants and has led pioneering projects in the fields of vascular biology and cancer research.
Current biologics are striking precision therapeutics, quite magical in design, specificity and functionalities
But not so much once in the body where barriers can thwart target access, precise targeting & full efficacy
Need to define real targeting and why we fail so often. What are the main barriers in vivo? How do they limit efficacy and expand toxicities? What can be done?
An active delivery paradigm for biologics, drugs and even nanoparticles to penetrate one solid tissue in minutes with >50% of iv dose & 1000x more potency.